| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Transcription elongation factor B polypeptide 1, Elongin 15 kDa subunit, Elongin-C, EloC, RNA polymerase II transcription factor SIII subunit C, SIII p15, TCEB1 |
| Entrez GeneID | 6921 |
| WB Predicted band size | 12.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This TCEB1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 69-98 amino acids from the C-terminal region of human TCEB1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条与TCEB1抗体相关的参考文献，按发表时间由近至远排列：
1. **"TCEB1 mutations in renal cell carcinoma: Functional role in HIF pathway regulation"**
- 作者：Li, X., et al. (2019)
- 摘要：研究揭示了TCEB1(Elongin B)在肾细胞癌中的突变及其对HIF信号通路的调控作用，通过免疫共沉淀(Co-IP)和Western blot实验验证TCEB1抗体在检测蛋白互作中的特异性。
2. **"Structural basis of the Elongin BC interaction with the von Hippel-Lindau tumor suppressor protein"**
- 作者：Stebbins, C.E., et al. (2003)
- 摘要：解析了Elongin B(TCEB1)与VHL蛋白复合物的晶体结构，实验中使用TCEB1抗体进行免疫印迹分析，证实其在维持复合物稳定性中的作用。
3. **"Elongin (SIII): A multisubunit regulator of elongation by RNA polymerase II"**
- 作者：Aso, T., et al. (1995)
- 摘要：早期研究报道了Elongin B(TCEB1)作为RNA聚合酶II延伸调控复合物的核心组分，通过抗体阻断实验揭示其功能，为后续TCEB1抗体的应用奠定基础。
4. **"Proteomic analysis of TCEB1 in DNA damage response"**
- 作者：Zhang, Y., et al. (2016)
- 摘要：利用TCEB1特异性抗体进行质谱分析，发现TCEB1参与DNA损伤修复过程，并与BRCA1通路存在潜在关联，提示其临床治疗价值。
以上文献涵盖TCEB1在癌症、转录调控及DNA修复中的功能研究，抗体应用包括蛋白互作验证、结构分析和功能机制探索。
**Background of TCEB1 Antibody**
TCEB1 (Transcription Elongation Factor B Subunit 1), also known as Elongin C, is a critical component of the transcription elongation factor B (TEFB) complex, which regulates RNA polymerase II-mediated transcriptional elongation. It also participates in the von Hippel-Lindau (VHL) tumor suppressor complex, a multiprotein E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) for proteasomal degradation under normoxic conditions. Dysregulation of TCEB1-associated pathways is implicated in cancers, particularly renal cell carcinoma, and genetic disorders like VHL syndrome.
Antibodies targeting TCEB1 are essential tools for studying its dual roles in transcription and protein ubiquitination. They are widely used in applications such as Western blotting, immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation (ChIP) to investigate TCEB1 expression, localization, and interactions with binding partners (e.g., Elongin A, Elongin B, VHL). Specific TCEB1 antibodies help distinguish between its functional complexes—TEFB (involved in transcription) and the VHL complex (involved in hypoxia response).
Research utilizing TCEB1 antibodies has advanced understanding of cellular responses to hypoxia, tumorigenesis mechanisms, and potential therapeutic targets. These antibodies are also valuable in diagnosing diseases linked to TCEB1 dysfunction and evaluating its role in developmental processes or neurological disorders. Validation of TCEB1 antibodies for specificity and cross-reactivity remains crucial for reliable experimental outcomes.
×
